HMGB1 Release From Hemorrhagic Shock Patients

Intensive Care Unit Clinical Trial

Official title:

Evidence for SIRT1 Mediated HMGB1 Release From Kidney Cells in the Early Stages of Hemorrhagic Shock

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03535441
• Other study ID #: HSHMGB12018
• Status: Completed
• Start date: May 17, 2017
• Est. completion date: May 11, 2018

Study information

• Verified date: May 2018
• Source: First People's Hospital of Chenzhou
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

It is reported that high mobility group box 1 (HMGB1), a non-histone nuclear protein, can serve as an alarmin with damage associated molecular patterns to activate immune responses in the early stages of hemorrhagic shock (HS). However, the origin of HMGB1 and how it is released following HS is poorly understood. In this study, we teased out this mechanism. We try to record the concentration of serum HMGB1 protein following HS in clinical patients.

Description:

The study was approved by the First People's Hospital of Chenzhou, Hunan, P.R. China. Consent was obtained from patients in their hospital course. Eighteen patients were enrolled for each group. In addition, Acute Physiological and Chronic Health Evaluation II (APACHE II) score was used to evaluate the severity and morbidity of HS patients Serial blood samples were collected at indicated time points on hospital admission for HS patients (0, 2, 4, 8, 24, and 72 h following HS). Levels of HMGB1 were detected by ELISA according to the kit manufacturer's instructions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: May 11, 2018
• Est. primary completion date: April 11, 2018
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Hemorrhagic shock (HS) was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more.

Exclusion Criteria:

pregnancy, <18 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital

Related Conditions & MeSH terms

• Adult Disease
• Hemorrhagic Shock
• Intensive Care Unit
• Shock
• Shock, Hemorrhagic

Locations

Country	Name	City	State
China	The First Hospital of Chenzhou	Chenzhou	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Xingui Dai

Country where clinical trial is conducted

China, 

References & Publications (4)

Hwang JS, Choi HS, Ham SA, Yoo T, Lee WJ, Paek KS, Seo HG. Deacetylation-mediated interaction of SIRT1-HMGB1 improves survival in a mouse model of endotoxemia. Sci Rep. 2015 Nov 2;5:15971. doi: 10.1038/srep15971. — View Citation

Hwang JS, Lee WJ, Kang ES, Ham SA, Yoo T, Paek KS, Lim DS, Do JT, Seo HG. Ligand-activated peroxisome proliferator-activated receptor-d and -? inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1. Cell Death — View Citation

Rabadi MM, Xavier S, Vasko R, Kaur K, Goligorksy MS, Ratliff BB. High-mobility group box 1 is a novel deacetylation target of Sirtuin1. Kidney Int. 2015 Jan;87(1):95-108. doi: 10.1038/ki.2014.217. Epub 2014 Jun 18. — View Citation

Rickenbacher A, Jang JH, Limani P, Ungethüm U, Lehmann K, Oberkofler CE, Weber A, Graf R, Humar B, Clavien PA. Fasting protects liver from ischemic injury through Sirt1-mediated downregulation of circulating HMGB1 in mice. J Hepatol. 2014 Aug;61(2):301-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	serum HMGB1 concentration	the concentration of serum HMGB1 were progressively increased following Hemorrhagic shock	24 hours following hemorrhagic shock